- Arrowhead reported plozasiran showed sustained triglyceride cuts and acceptable safety in its RNAi cardiometabolic program, per the company’s ongoing data readout.
- Arrowhead Pharmaceuticals (ARWR) advances its cardiometabolic pipeline, highlighting the launched REDEMPLO lipid program and ongoing development of related cardiometabolic assets.
TradingView
Key facts: Arrowhead plozasiran lowers triglycerides; REDEMPLO launched
Arrowhead reported plozasiran showed sustained triglyceride cuts and acceptable safety in its RNAi cardiometabolic program, per the company’s ongoing data readout.Arrowhead Pharmac